接受经皮冠状动脉介入治疗的心肌梗死和多支血管疾病患者接受完全冠状动脉血运重建还是仅接受罪魁祸首冠状动脉血运重建:最新荟萃分析。

IF 4.3 4区 医学 0 MEDICINE, GENERAL & INTERNAL
Alfredo M Rodriguez-Granillo, Walter Masson, Martin Lobo, Juan Mieres, Lisandro Pérez-Valega, Leandro Barbagelata, Karen Waisten, Carlos Fernández-Pereira, Alfredo E Rodriguez
{"title":"接受经皮冠状动脉介入治疗的心肌梗死和多支血管疾病患者接受完全冠状动脉血运重建还是仅接受罪魁祸首冠状动脉血运重建:最新荟萃分析。","authors":"Alfredo M Rodriguez-Granillo, Walter Masson, Martin Lobo, Juan Mieres, Lisandro Pérez-Valega, Leandro Barbagelata, Karen Waisten, Carlos Fernández-Pereira, Alfredo E Rodriguez","doi":"10.23736/S0031-0808.24.05267-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Recently, the FFR-Guidance for Complete Nonculprit Revascularization (FULL REVASC) trial in ST elevation myocardial infarction (STEMI) patients with multiple vessel disease (MVD) did not show differences in the composite endpoint of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only percutaneous coronary intervention (PCI) at 4.8 years, although complete revascularization is a recommendation IA in current guidelines. We want to determine through an updated meta-analysis whether complete revascularization is associated with decreased mortality and hard clinical endpoints compared to culprit lesion only PCI.</p><p><strong>Evidence acquisition: </strong>We searched MEDLINE, Embase, ISI Web of Science, and Cochrane Central Register of Controlled Trials) from January 1990 to April 2024 using the terms \"percutaneous coronary intervention\" combined with \"non culprit lesions\" or \"culprit lesion\" or \"complete revascularization\" or \"incomplete revascularization.\" Additionally, a \"snowball search\" was conducted. Only randomized clinical trials (RCT) reporting mortality, re-infarction or new revascularization after at least 12 months and using predominantly drug eluting stents were included. The summary effect of different revascularization strategies on cardiovascular endpoints was estimated and measures of effect size were expressed as odds ratios (ORs).</p><p><strong>Evidence synthesis: </strong>Eight RCT involving 9515 patients were included, with a follow-up range between 12 months and 4.8 years. Main findings show that culprit lesion revascularization was associated with an increased risk of MI (OR: 1.38; 95% CI: 1.05 to 1.81, I2 42%) and ischemia-guided revascularization (OR: 2.81; 95% CI: 1.86 to 4.26, I2 80%) compared to complete revascularization, without differences in overall mortality (OR: 1.15; 95% CI: 0.98 to 1.36, I2 2%).</p><p><strong>Conclusions: </strong>In patients with STEMI and MVD without cardiogenic shock, our metanalysis showed that complete revascularization with PCI significantly reduced the risk of non-fatal myocardial reinfarction and ischemic-driven revascularization compared to culprit vessel-only revascularization, without differences in overall mortality.</p>","PeriodicalId":19851,"journal":{"name":"Panminerva medica","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complete versus culprit-only coronary revascularization in patients with myocardial infarction and multivessel disease undergoing percutaneous coronary intervention: an updated meta-analysis.\",\"authors\":\"Alfredo M Rodriguez-Granillo, Walter Masson, Martin Lobo, Juan Mieres, Lisandro Pérez-Valega, Leandro Barbagelata, Karen Waisten, Carlos Fernández-Pereira, Alfredo E Rodriguez\",\"doi\":\"10.23736/S0031-0808.24.05267-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Recently, the FFR-Guidance for Complete Nonculprit Revascularization (FULL REVASC) trial in ST elevation myocardial infarction (STEMI) patients with multiple vessel disease (MVD) did not show differences in the composite endpoint of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only percutaneous coronary intervention (PCI) at 4.8 years, although complete revascularization is a recommendation IA in current guidelines. We want to determine through an updated meta-analysis whether complete revascularization is associated with decreased mortality and hard clinical endpoints compared to culprit lesion only PCI.</p><p><strong>Evidence acquisition: </strong>We searched MEDLINE, Embase, ISI Web of Science, and Cochrane Central Register of Controlled Trials) from January 1990 to April 2024 using the terms \\\"percutaneous coronary intervention\\\" combined with \\\"non culprit lesions\\\" or \\\"culprit lesion\\\" or \\\"complete revascularization\\\" or \\\"incomplete revascularization.\\\" Additionally, a \\\"snowball search\\\" was conducted. Only randomized clinical trials (RCT) reporting mortality, re-infarction or new revascularization after at least 12 months and using predominantly drug eluting stents were included. The summary effect of different revascularization strategies on cardiovascular endpoints was estimated and measures of effect size were expressed as odds ratios (ORs).</p><p><strong>Evidence synthesis: </strong>Eight RCT involving 9515 patients were included, with a follow-up range between 12 months and 4.8 years. Main findings show that culprit lesion revascularization was associated with an increased risk of MI (OR: 1.38; 95% CI: 1.05 to 1.81, I2 42%) and ischemia-guided revascularization (OR: 2.81; 95% CI: 1.86 to 4.26, I2 80%) compared to complete revascularization, without differences in overall mortality (OR: 1.15; 95% CI: 0.98 to 1.36, I2 2%).</p><p><strong>Conclusions: </strong>In patients with STEMI and MVD without cardiogenic shock, our metanalysis showed that complete revascularization with PCI significantly reduced the risk of non-fatal myocardial reinfarction and ischemic-driven revascularization compared to culprit vessel-only revascularization, without differences in overall mortality.</p>\",\"PeriodicalId\":19851,\"journal\":{\"name\":\"Panminerva medica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Panminerva medica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S0031-0808.24.05267-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Panminerva medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0031-0808.24.05267-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

导言:最近,针对ST段抬高心肌梗死(STEMI)伴多支血管病变(MVD)患者的FFR-指导完全非病灶性血管再通(FULL REVASC)试验在4.8年时,与单纯病灶经皮冠状动脉介入治疗(PCI)相比,在任何原因导致的死亡、心肌梗死或非计划性血管再通的复合终点方面未显示出差异,尽管完全血管再通是当前指南中的推荐IA。我们希望通过一项最新的荟萃分析来确定,与仅对罪魁祸首病变进行 PCI 相比,完全血运重建是否与死亡率和硬性临床终点的降低有关:我们检索了1990年1月至2024年4月期间的MEDLINE、Embase、ISI Web of Science和Cochrane Central Register of Controlled Trials),检索时使用了 "经皮冠状动脉介入治疗 "和 "非罪魁病变 "或 "罪魁病变 "或 "完全血管再通 "或 "不完全血管再通 "等术语。此外,还进行了 "滚雪球式搜索"。只有报告了至少 12 个月后的死亡率、再梗死或新的血管再通情况且主要使用药物洗脱支架的随机临床试验(RCT)才被纳入。对不同血管再通策略对心血管终点的影响进行了估算,并以几率比(ORs)表示效应大小:证据综述:共纳入了 8 项 RCT,涉及 9515 名患者,随访时间从 12 个月到 4.8 年不等。主要研究结果显示,与完全血管重建相比,罪魁祸首病变血管重建与心肌梗死风险增加(OR:1.38;95% CI:1.05 至 1.81,I2 42%)和缺血引导下血管重建风险增加(OR:2.81;95% CI:1.86 至 4.26,I2 80%)相关,但总体死亡率无差异(OR:1.15;95% CI:0.98 至 1.36,I2 2%):我们的荟萃分析表明,对于 STEMI 和 MVD 且无心源性休克的患者,与单纯罪魁祸首血管再通术相比,PCI 完全再通术可显著降低非致命性心肌再梗死和缺血性驱动再通术的风险,但总体死亡率没有差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Complete versus culprit-only coronary revascularization in patients with myocardial infarction and multivessel disease undergoing percutaneous coronary intervention: an updated meta-analysis.

Introduction: Recently, the FFR-Guidance for Complete Nonculprit Revascularization (FULL REVASC) trial in ST elevation myocardial infarction (STEMI) patients with multiple vessel disease (MVD) did not show differences in the composite endpoint of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only percutaneous coronary intervention (PCI) at 4.8 years, although complete revascularization is a recommendation IA in current guidelines. We want to determine through an updated meta-analysis whether complete revascularization is associated with decreased mortality and hard clinical endpoints compared to culprit lesion only PCI.

Evidence acquisition: We searched MEDLINE, Embase, ISI Web of Science, and Cochrane Central Register of Controlled Trials) from January 1990 to April 2024 using the terms "percutaneous coronary intervention" combined with "non culprit lesions" or "culprit lesion" or "complete revascularization" or "incomplete revascularization." Additionally, a "snowball search" was conducted. Only randomized clinical trials (RCT) reporting mortality, re-infarction or new revascularization after at least 12 months and using predominantly drug eluting stents were included. The summary effect of different revascularization strategies on cardiovascular endpoints was estimated and measures of effect size were expressed as odds ratios (ORs).

Evidence synthesis: Eight RCT involving 9515 patients were included, with a follow-up range between 12 months and 4.8 years. Main findings show that culprit lesion revascularization was associated with an increased risk of MI (OR: 1.38; 95% CI: 1.05 to 1.81, I2 42%) and ischemia-guided revascularization (OR: 2.81; 95% CI: 1.86 to 4.26, I2 80%) compared to complete revascularization, without differences in overall mortality (OR: 1.15; 95% CI: 0.98 to 1.36, I2 2%).

Conclusions: In patients with STEMI and MVD without cardiogenic shock, our metanalysis showed that complete revascularization with PCI significantly reduced the risk of non-fatal myocardial reinfarction and ischemic-driven revascularization compared to culprit vessel-only revascularization, without differences in overall mortality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Panminerva medica
Panminerva medica 医学-医学:内科
CiteScore
5.00
自引率
2.30%
发文量
199
审稿时长
>12 weeks
期刊介绍: Panminerva Medica publishes scientific papers on internal medicine. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work. Duties and responsibilities of all the subjects involved in the editorial process are summarized at Publication ethics. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (ICMJE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信